Key Takeaways
- • Pearl Diagnostics, a Johns Hopkins spinout, raised $11.5M in funding to commercialize its FDA-approved urine test for detecting deadly fungal infections, which secured regulatory approval in August 2025.
- • The company is actively seeking a European distribution partner to expand its product internationally following successful U.S. market entry.
- • The funding round positions Pearl Diagnostics to move from development stage to commercial-stage operations with its first FDA-cleared diagnostic product now ready for market deployment.
Summary
Pearl Diagnostics, a diagnostic company spun out from Johns Hopkins University, has closed an $11.5 million funding round to bring its flagship product to market. The company obtained FDA approval in August 2025 for a urine-based test designed to detect serious fungal infections, clearing a critical regulatory hurdle for commercial launch.
The Baltimore-based firm is leveraging the capital infusion to execute its go-to-market strategy and establish commercial operations. Beyond domestic expansion, Pearl Diagnostics is actively pursuing partnership discussions with European distribution partners to secure international market access for its diagnostic test, indicating a phased geographic expansion approach typical of early-stage medical device companies seeking to maximize market penetration while managing operational scale.
This funding milestone reflects the maturation of the company from development to revenue-generating stage. The transition from FDA approval to funded commercialization suggests investor confidence in both the product's clinical utility and market demand for improved fungal infection diagnostics. For institutional investors tracking the diagnostic innovation landscape, Pearl Diagnostics represents an example of academic institution technology transfer resulting in venture-backed commercial enterprises with clear regulatory clearance and defined commercialization pathways.
The Baltimore-based firm is leveraging the capital infusion to execute its go-to-market strategy and establish commercial operations. Beyond domestic expansion, Pearl Diagnostics is actively pursuing partnership discussions with European distribution partners to secure international market access for its diagnostic test, indicating a phased geographic expansion approach typical of early-stage medical device companies seeking to maximize market penetration while managing operational scale.
This funding milestone reflects the maturation of the company from development to revenue-generating stage. The transition from FDA approval to funded commercialization suggests investor confidence in both the product's clinical utility and market demand for improved fungal infection diagnostics. For institutional investors tracking the diagnostic innovation landscape, Pearl Diagnostics represents an example of academic institution technology transfer resulting in venture-backed commercial enterprises with clear regulatory clearance and defined commercialization pathways.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.